Navigation Links
ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Date:1/30/2013

ng from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the prospects for ANX-188's clinical, regulatory and commercial success in sickle cell disease, including that ANX-188 may be the first FDA-approved product for sickle cell disease in several years, that the orphan-drug designation for poloxamer 188 (purified) is expected provide ANX-188 with seven years of post-approval exclusivity in the U.S., that fast track designation may result in a shortened timeframe for FDA review of a new drug application for ANX-188, and the potential for ANX-188 to be designated a drug for a rare pediatric disease and for ADVENTRX to receive a priority review voucher.  Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the risk that the rate of enrollment in the EPIC study is slower than was anticipated prior to the study's initiation, including as a result of delays in opening study sites and difficulties in recruiting study subjects; the potential for further delays in the commencement or completion of planned clinical studies, including the phase 3 study of ANX-188 in sickle cell disease, including as a result of difficulties in completing manufacturing process development activities, manufacturing sufficient quantities of clinical trial material, meeting applicable regulatory requirements for clinical trial material, meeting applicable requirements of
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
2. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
3. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
4. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
5. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
6. ADVENTRX Announces Appointment Of Chief Medical Officer
7. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
8. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
9. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
10. ADVENTRX Reports Third Quarter 2012 Financial Results
11. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... According to a new ... Market Study on Physiotherapy Equipment - ... 2022", the global physiotherapy equipment market is estimated to be ... and is expected to grow at a CAGR ... for US$23.7 Bn by 2022. View Full ...
(Date:8/3/2015)... VWR (NASDAQ: VWR ), a ... the redesign of its global website, www.vwr.com , to ... the new site, guests will enjoy enhanced content on a ...  Each country site now includes: , a ... and , the ability to search by discipline/industry. ...
(Date:8/3/2015)... Florida , August 3, 2015 ... -- FN Media Group LLC, PIV757417 The following ... on Developing Orphan Drug Products & Treatments for ... OFF HOLD. Distribution time: 3 Aug 2015 12:30 ... between biotech companies, military surgical research and top-tier ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6
... 14, 2010 VIVUS, Inc. (Nasdaq: VVUS ) ... effort to secure regulatory approval for QNEXA® in the U.S., ... (FDA) designed to address items in the FDA,s Complete Response ... announced that the Endocrine and Metabolic Division of the FDA ...
... Science, Inc. (OTC Bulletin Board: CBIS ) a ... to announce it has signed a lease for a new ... Colorado. The 6,600 sq. ft. core facility at 2422 S. ... offices, administrative personnel, as well as the Lab Division core ...
Cached Medicine Technology:VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 3Cannabis Science Signs Lease for New 6,600 sq. ft. Corporate Headquarters and Laboratory Facility 2Cannabis Science Signs Lease for New 6,600 sq. ft. Corporate Headquarters and Laboratory Facility 3
(Date:8/3/2015)... ... 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ), the ... healthcare information exchange, announced the release of its findings from its June 2015 ICD-10 ... WEDI shared survey results and recommendations , strongly encouraging the department ...
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor & Kantor, LLP announced ... firm’s client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement ... residential treatment for bulimia, depression and other mental health problems. , According to ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent ... overwhelming number of Hispanics believe people can positively affect their diabetes, few look ... queried said making diet changes was important. Far fewer participants mentioned the need ...
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s ... Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. The ... aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the Fall ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4
... stroke a major issue in analysis of 33 research projects ... 33 studies on drugs known as beta blockers has concluded ... than heart surgery. In fact, using beta blockers for non-coronary ... say. , The researchers who conducted the study -- known ...
... bypass does not cause short-term neurological problems in ... heart defects, according to pediatric researchers. The new ... adverse neurological effects after newborn surgery for more ... for school-aged children who receive surgery for these ...
... WASHINGTON, Nov. 10 A Guide to Implementing,GASB 45, a ... Government,Excellence, examines how North Carolina local governments are meeting their,obligations ... issue brief, which is based on a survey of the ... $100 million, reports that:, -- 88 percent ...
... -- Net Revenue Increased 93.6% to US$146.5 million; Non-GAAP Gross Margins ... ... Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ), ... its selected,unaudited financial results for the third quarter and nine months ...
... (Amex: IMM ) today announced results for its ... three months ended September 30, 2008, revenues were $506,000,as ... 30, 2007.,The decrease was primarily attributable to revenues from ... three months ended,September 30, 2008 was $2,446,000, as compared ...
... leads to more bleeding, longer hospital stay, study finds , , ... the clot-preventing drug Plavix less than five days before having ... more likely to require a second operation, and will spend ... current guidelines. , Those guidelines from the American College of ...
Cached Medicine News:Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3Health News:No drop in IQ seen after bypass for child heart surgery 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 3Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 4Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 5Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 6Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 7Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 8Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 9Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 10Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 11Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 12Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 13Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 14Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 15Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 16Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 17Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 18Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 19Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 20Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 21Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 22Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 23Health News:Immtech Reports Fiscal Second Quarter 2009 Results 2Health News:Immtech Reports Fiscal Second Quarter 2009 Results 3Health News:Study Upholds Stopping Plavix Use Before Surgery 2
Double cuff electronic tourniquet....
... Safety. Convenience. Reliability. Cost. These are ... OR personnel, and administrators. With a special ... most practical elements of todays technology to ... , The A.T.S. 2000 Tourniquet uses ambient ...
... a revolutionary new addition to the Hall® ... PowerPro Battery System is the first and ... on the market. It is a full-function ... the requirements of large bone, small bone, ...
Stryker Instruments, the leader in cordless power, advances orthopaedics with the power, speed, versatility, reliability and performance through its heavy duty powered instruments....
Medicine Products: